



Making drug screening as routine as the alcohol check

Goal: Raising CHF 1.8M, 500k already committed

Leonard Dumea, MD
Founder & CEO
l.dumea@altiscreen.com

Florian Saner
Co-Founder & CFO
f.saner@altiscreen.com

altiscreen.com



Why Drug-Impaired Drivers Evade Detection

The enforcement gap



4–15% of drivers are drug-positive

15–25% of all road deaths are drug abuse related

Systematic field drug screening is rare
Thousands of impaired drivers slip through undetected

Sources: [DRUID](#), [DRUID final report](#), [EU/EUDA](#), [PLOS](#), [EU Commission](#), [WHO – Global status](#), [WHO – Fact Sheet](#), [OECD/ITF](#), [European Transport Safety Council](#)

Current Tools Ground Officers

Altiscreen sets them free



Existing solutions don't work in real police workflow.

Bulky, Slow



Impractical



Complex



Officers have no practical tool—so they skip drug testing entirely.

Closing the gap

Altiscreen offers functional, field-validated solutions



Enables immediate, on-site, 5x more tests per shift

Ready in 30 seconds

No vehicle setup, no training required

Result in 3 minutes

Vs. 10-15 min. avg. for competition

Large detection panel

Up to 9 substances at once vs. max 6 for competition



Police of Paris with our Altiscreen A1 device

Our technology platform

Lateral flow assay with computer vision-enhanced image processing



Screening device, reduces false results that need to be confirmed in a lab

Results type

Currently - qualitative

2026 - Roadmap toward semi-quantitative results

Focusing on Drugs of Abuse

We develop market specific tests according to the local legislation

OM60*

Cannabinoids

Amphetamine

Methamphetamine

Ecstasy


Cocaine

Opiates/Opioids

**Customizable panel of detectable substances*

Science behind our product


Transforming concentration into objective data




Substance
(Concentration)




Visual signal
(Immunochromatography)



Computer analysis
(Computer vision, AI)



Qualitative
Or Semi-quantitative result



Proprietary technology

Device

- FTO – OK
- Two Patents filed – protecting the only efficient way of handheld detection
- One Design application granted, a second one in progress

Consumable

Proprietary oral fluid collection cartridge

- New patent under filing - novel collection method reduces processing time (50% improvement)

Recent improvements – device in pocket size



Competitive advantage

Altiscreen A1 - Operated entirely in hand, like a breathalyzer




| | | Brand strength | Portability | Analyze setup | Analyse time | Detection quality NHTSA Report* | Price |
|---|--|----------------|-------------|-------------------------|--------------|--|--------------------------------|
| Dräger DrugTest® 5000 (Launched 2009) | | Strong | 4.5 kg | Flat surface | 10-15 min | 80-100% | 3000 € Device 30 € Test kit |
| Abbott SoToxa (Launched 2004 multiple take-overs) | | Strong | 0.9 kg | Flat surface | 10-15 min | 60-80% | 4000 € Device 25 € Test kit |
| Securetec WipeAlyser® (Launched 2018; Archiving tool) | | Average | 0.8 kg | Flat surface | 10 min | 40-60%** | 3500 € Device 20 € Test kit |
| Visual testing | | Poor | 0.05 kg | Mixed Flat s. / hand | 3-10 min | 30-60% | No Device 12 € Test kit |
| Altiscreen A1 | | Emerging | 0.3 kg | In hand | 3 min | 80-100% independent tests | 4000 € Device 19 € Test kit |

*National Highway Traffic Safety Administration, April 2021 Evaluation
 **Large number of false negatives

Competitive advantage


Dräger Drug Test 5000 – main competitor in France



300g

4.5kg

Device



4 parts kit

Simple kit

Consumable

Market Sizing (2030)

Drugs of Abuse screening market growing continuously, CAGR 4.1%



Altiscreen focuses on the handheld slice of a fast-growing roadside market (CAGR 5,95%).



Drugs Screening Total Available Market
(All places, sizes and weights, portable or not)

\$ 11.9 billion
(from US\$ ~9.4 billion in 2024)



Portable, handheld roadside devices
(Duty belt capable and operated in-hand)

\$ 3 billion



Altiscreen 2030 revenue
(Sales of 5000 screening devices and 1.2 million test kits)

\$ 34 million

Focus



Law enforcement

Expansion 2029



Army




Firehouse



Workplace

Roadmap

From MVP to Market



30/03/2026

Team

The right expertise to scale up



Leonard Dumea, MD

100%

CEO, Co-founder
Head of Sales



Florian Saner

80%

CFO, Co-founder
Planning, Investor, Accounting



Robin Koller

40%

Marketing Manager
Online, SEO



Michèle Ruet

20%

Marketing Manager
Offline, Branding



Samuel Bapst
20% (100% in May)

Sales Representative
FR/CH



Aleksandar Rajković

20%

Software developer



Goran Temunovic

50%

Product Manager



Sabine Hanser
20% (60% in July)


Production / Customer care

Our Network

Scaling up tested and ready



Advisors



**Scientific Advisor
(KOL contract)**

Eminent toxicology professor



Guillaume Renoud

R&D Advisor
(Lateral Flow Expert)



Hans Schmotzer

IP Advising & Management



Laurent Monnerat

Corporate,
Business development



Camille Andre

Corporate Business
Development

Business Development



Cold calling
Lead generation
FR/CH



Automation
consumable assembly



Hardware-software
development



Devices assembly



R&D

Regulatory (IVDR Class A)



QMS, MDF
Internal audits



External audits

US Market Access





Nat Bowditch

MedTech Market access specialist

Financing – Protecting investor equity

Clear strategy to become the world leader in Handheld Drug Screening



Seed round of CHF 1.8M to scale commercial operations

Focus on market development and production



Achievements


- 33 pilots being deployed in France
- Sales pipeline in CH, FR, BE, ES
- Set up of sales & marketing channels
- Team expanded
- IP expanded, QMS audited
- CE Marking
- Production and supply chain in place

28% already signed

We are looking for :

- CHF 1,300,000 investment
- A lead investor

Financing round closing end of June 2026



Thank you!



From left to right:
Milipol Paris – Robin, Camille, Leo



Transforming Handheld Drugs of Abuse Screening

Leonard Dumea, MD
Founder & CEO
l.dumea@altiscreen.com

Florian Saner
Co-Founder & CFO
f.saner@altiscreen.com

altiscreen.com